Lymphopenia is a condition in which there is a lower-than-normal number of lymphocytes (a type of white blood cell) in the blood. Also called lymphocytic leukopenia and lymphocytopenia.
In a preprint paper published on the medRxiv server, a team of researchers from various institutions in South Africa, the UK, and Europe discuss how they determined the impact of HIV on the COVID-19 immune response in KwaZulu-Natal, South Africa, which is an area with very high HIV prevalence.
Researchers from the Huazhong University of Science and Technology and Shanghai Jiao Tong University, China, recently built a proteome microarray with 20 out of the 28 predicted SARS-CoV-2 proteins to help understand IgM/IgG responses specific to SARS-CoV-2.
A preliminary analysis of photon therapy treatment group 1 from the phase II NRG Oncology clinical trial NRG-BN001 indicates that there is no statistically significant overall survival (OS) or toxicity differences between dose-intensification radiation therapy (DI-RT) using intensity-modulated radiation therapy (IMRT) and standard-dose radiation therapy (SD-RT) with temozolomide treatments for patients with newly diagnosed glioblastoma (GBM).
A team of scientists from the United Kingdom has revealed that markers of endothelial cell injury are associated with severe and fatal outcome of coronavirus disease 2019 (COVID-19). The study is currently available on the medRxiv* preprint server.
In a study by researchers explored the possible mechanisms of the clotting disorder, focusing on the role of hypoxia-related activation of coagulation factors; cytokine storm, activation of neutrophils, and the release of neutrophil extracellular traps.
A team of researchers from Aix-Marseille Univ, IHU-Méditerranée Infection, Institut Paoli Calmettes and Laboratoire d’Immunologie, Marseille, France, conducted experiments to determine if SARS-CoV-2 can affect the myeloid compartment or infect monocytes and macrophages.
To predict severe outcome in COVID-19 patients, innate immune cellular signals are analyzed, identifying two novel neutrophil subsets: LOX-1- and CD123-expressing CD10-CD64+. Thromboembolic events correlated with high LOX-1 immature neutrophils – a potential prognostic signature.
Now, a new study published on the preprint server medRxiv* reports the use of D-dimer in predicting the risk of mortality in COVID-19.
The age-related increase in the risk of severe disease and death from COVID-19 mirrors earlier patterns seen with infections. Such trends may help understand the mechanisms underlying the clinical feature. A recent study published in the preprint server medRxiv* in August 2020 shows the effect of age and sex on COVID-19 hospitalization rates in the USA and helps understand how immune function is involved in this pandemic.
A new study by a large team of Spanish researchers and published on the preprint server medRxiv* in August 2020 reports that the presence of viral RNA in the blood is a useful marker of impending acute disease and can help triage COVID-19 disease patients who will require hospital care.
For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of participants in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of Texas MD Anderson Cancer Center.
The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread and cause disease and death in many countries even today. At present, there is no effective treatment. A recent study published on the preprint server bioRxiv in August 2020 reports the potential of a new class of drugs called CAR NK cells, which could be used off-the-shelf to treat this disease.
A recent case study published in the Journal of Applied Laboratory Medicine in August 2020 illustrates this with its finding of persistent seronegativity in a patient confirmed to be SARS-CoV-2 positive.
Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection often complain of fatigue, but now a new study shows that it also causes severe and frequent fatigue in those who recover after mild illness too.
Now, a new study by researchers at Saarland University, Germany, and published on the preprint server medRxiv in July 2020 shows that there are higher levels of anti-SARS-CoV-2 T cells, which show significant alterations in the phenotype and function.
A cellular therapy tested on 13 intubated patients with mechanical ventilation has shown to be efficient for the clinical improvement of critical cases of COVID-19.
As experts in hematology HORIBA UK Ltd, Medical announces that the Company has published a white paper entitled, ‘COVID-19 screening, prognosis and severity assessment with biomarkers for management of patients’.
A new study published on the preprint server medRxiv in June 2020 describes differences in the adaptive and innate immune response in mild, moderate, and severe COVID-19. This may mean that permanent immune responses occur only in patients who recover from severe COVID-19.
A new study published on the preprint server bioRxiv in June 2020 shows that T cell responses in COVID-19 patients are broader and more robust in severe disease and are explicitly directed against spike, memory, and ORF3a proteins.
A new study by researchers in the Netherlands and published on the preprint server bioRxiv in June 2020 describes the differences in T and B cell responses seen in patients with severe COVID-19.